Evgen Pharma Share Price (EVG)

Share Name	Share Symbol	Market	Type	Share ISIN	Share Description
Evgen Pharma Plc	LSE:EVG	London	Ordinary Share	GB00BSVYN304	ORD 0.25P

	Price Change	% Change	Share Price	Shares Traded	Last Trade
	0.00	0.0%	14.375	0.00	01:00:00

Bid Price		Offer Price	High Price	Low Price	Open Price
14.00		14.75	0.00	0.00	0.00

Industry Sector	Turnover (m)	Profit (m)	EPS - Basic	PE Ratio	Market Cap (m)
Pharmaceuticals & Biotechnology		-3.12	-2.74		19

Last Trade Time	Trade Type	Trade Size	Trade Price	Currency
-	O	0	0.00	GBX

Related Shares
Astrazeneca (AZN), Glaxosmithkline (GSK), Agronomics (ANIC), Valirx (VAL)

Evgen Pharma (EVG) Latest News

Evgen Pharma News

Date	Time	Source	Headline
30/9/2019	07:59	ALNCF	Alliance News Flash Headline
30/9/2019	07:00	UKREG	Evgen Pharma PLC ESMO presentation of Phase II STEM clinical data
23/9/2019	13:09	ALNC	Evgen Pharma "Delighted" With Extended Breast Cancer Treatment Results
23/9/2019	07:00	UKREG	Evgen Pharma PLC Update on extended-use phase of STEM trial
05/9/2019	13:39	ALNC	Evgen Pharma To Supply Lead Candidate SFX-01 In Possible Autism Trial
05/9/2019	07:00	UKREG	Evgen Pharma PLC Agreement for supply of SFX-01 for autism trial
28/8/2019	12:06	ALNC	Evgen Pharma Receives Last Patient For Stroke Treatment Drug Trial
28/8/2019	07:00	UKREG	Evgen Pharma PLC Update on SAS study
07/8/2019	11:47	ALNC	Evgen Pharma Gets European Patent Covering Composition Of SFX-01
07/8/2019	07:00	UKREG	Evgen Pharma PLC Grant of further European patent

More Evgen Pharma News

Evgen Pharma Takeover Rumours

Evgen Pharma (EVG) Share Charts

1 Year Evgen Pharma Chart

1 Month Evgen Pharma Chart

Intraday Evgen Pharma Chart

Evgen Pharma (EVG) Discussions and Chat

Evgen Pharma Forums and Chat

Date	Time	Title	Posts
21/10/2019	13:56	Evgen Pharma: Developing Sulforaphane to treat Stroke, MS and Cancer	1,303
17/6/2018	15:42	Interview and Q&A with Evgen Pharma	2
26/6/2017	07:38	Evgen Pharma Plc Investor Presentation	-
13/6/2017	09:45	Evgen Pharma Interview	-
29/11/2016	08:27	Evgen Pharma (EVG) chief executive Stephen Franklin	39

Add a New Thread

Evgen Pharma (EVG) Most Recent Trades

Trade Time	Trade Price	Trade Size	Trade Value	Trade Type
2019-10-22 12:30:34	14.00	5,475	766.50	O
2019-10-22 08:30:38	14.00	5,000	700.00	O
2019-10-22 08:04:09	14.13	15,000	2,118.75	O
2019-10-22 08:04:04	14.13	15,000	2,118.75	O
2019-10-22 07:55:20	14.50	12,234	1,773.93	O

View all Evgen Pharma trades in real-time

Evgen Pharma (EVG) Top Chat Posts

Date	Subject
22/10/2019 09:20	Evgen Pharma Daily Update: Evgen Pharma Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker EVG. The last closing price for Evgen Pharma was 14.38p. Evgen Pharma Plc has a 4 week average price of 13.75p and a 12 week average price of 13.75p. The 1 year high share price is 28.50p while the 1 year low share price is currently 13p. There are currently 132,646,263 shares in issue and the average daily traded volume is 492,710 shares. The market capitalisation of Evgen Pharma Plc is £19,067,900.31. Read Full Thread Reply
13/10/2019 13:18	pennyfalls: Problem is, the trading cycle becomes a self-fulfilling prophecy. Each item of good news (and there’s been many) brings an attendant spike, then slowly but surely back to the support levels circa 13.5p-15p (and maybe even testing an all-time low one this time), plus fundraiser. So investors see the well-defined pattern and act accordingly. However at some point there will be (should be) an inflection point where traction holds with the share price. This could be positive SAH + forward funding/licensing then Autism trials etc (coming in quick succession), or it could be further down the line at SAH phaseIII or next STEM trials. But all depends on the next RNS being a good one, so I’ll take it from there and see what comes Read Full Thread Follow Reply
11/10/2019 20:05	90005nelson: The Directors have good skin in the game here. There's also two chances of success with SFX-01 from STEM & SAH. EVG has stated that potential partners need to pay an upfront payment of $50M & &70M. Companies house has been fully updated. The removal of pre-emption rights. There's movement behind the scenes as we wait for the SAH results. Orphan drug status is obtained as with virtually all the worldwide patents. I don't expect the share price to be at this level within next few months. Read Full Thread Follow Reply
11/10/2019 19:40	pennyfalls: All posts look quite positive to me Dave, with some good knowledge. Outcome wont be linked to ADVFN posts, and neither will Share price. Read Full Thread Follow Reply
10/10/2019 15:05	90005nelson: I agree with your timeline for the news. LTH are also derisking as they watch previous profits evaporate.The share price is now below my average and represents 13.3% of my portfolio. I'm happy to divert other profits, as & when, into the lower price. Read Full Thread Follow Reply
26/9/2019 12:29	timbo003: A few thoughts following some of the recent comments on the SAH study First of all, it is worth bearing in mind the market’s perceived potential value (and risk adjusted value) of the company’s clinical assets: Finncap Initiation note (April 2019) Metastatic breast cancer value of (£30m) 30p per share that would rise to c.£60m (60p) on a successful Phase IIb study. This excludes any upfront licensing payment that would be expected on successful completion of the proposed Phase IIb study. This could be of the order of order of $50m or c.35-40p per share. The de-risked NPV is c.£300m (excluding upfronts and/or milestones). Subarachnoid haemorrhage value of £14m (15p per share). A positive readout of its Phase IIb study in Q3 2019 would value the potential royalty stream at c.£50m, which together with the value of a potential upfront payment (c.£30m), should the company license the asset, implies an asset value of c.£80m. Our target price attributes no value to any investigator-initiated studies in which Evgen would supply SFX-01 for Phase II trials in fatty liver disease (NASH), autism spectrum disorder and intra-cerebral haemorrhage (ICH) whilst retaining all commercial rights. Our target price valuation would rise to at least c.£80m (80p) on a successful Phase IIb trial result in SAH. The downside risk, should the trial fail, is around 7p in our opinion. The current share price is more than supported by the breast cancer indication alone (c.30p). Finncap update (May 2019) The Phase IIb trial of SFX-01 in subarachnoid haemorrhage (SAH) is expected to readout in Q3 2019, following advice from clinicians and statisticians to leave the study blinded until completion of both primary and secondary cognitive endpoints at six months post treatment. A successful outcome would see our risk-adjusted value for this indication rise from c.£15m to c.£80m. Our forecasts are unchanged apart from cash and LPS, which is reduced to take account of the 25% enlargement of share capital. Our target price is reduced to 35p to reflect this dilution. Our risk-adjusted target valuation of c.£45m would rise to c.£110m upon a successful Phase IIb readout for SAH, implying an increase in the target price to c.85p. On March 18th the company stated: Following advice from clinicians and statisticians, and in the light of commercial considerations, the Company has decided to announce the primary endpoints (safety, tolerability and measures of blood flow in the brain) and secondary endpoints (relating to cognitive function) at the same time, rather than announcing them separately as previously indicated. I would have been very surprised if they hadn’t taken that decision given the study design. The primary outcome is cerebral blood flow and one of the the secondary outcomes is cognitive function ( 7 , 28, 90 and 180 days post stroke). In reality, everyone (i.e. Clinicians, Investors and potential partners) will be far more focused on the secondary than the primary, so why compromise the blinding (and the statistical significance) for the outcome which is of most interest by prematurely analysing and reporting result from the primary measure (which will be of much less interest)? This is particularly relevant in the SAH study as the cognitive function will be assessed using the modified Rankin scale (0-6 ordinal scale) https://clinicaltrials.gov/ct2/show/NCT02614742?term=evgen&rank=2 This will inevitably involve some subjectivity when assigning a score (with the obvious exception of scoring a maximum 6), therefore it extremely important to maintain the integrity of the blinding https://en.wikipedia.org/wiki/Modified_Rankin_Scale http://www.modifiedrankin.com/input? Given the lack lustre share price action in the last few weeks, investors are bound to ask themselves, does someone already know the outcome of the study? I think the answer to that is almost certainly no, with the small caveat that in some blinded studies where the design is control vs active, it is sometimes possible for the investigator to make an educated guess as to whether the active is having any effect, for example when one of the outcomes is unavoidably obvious (for example mortality rate). For SAH on average around 40% of patients on standard of care die within 30 days and for the survivors c.50% will have long-term cognitive impairment, so if the investigator sees no perceptible improvement for these measures when looking at the combined blinded placebo and active treatments, they may come to the conclusion that the active treatment is probably ineffective, on the other hand if they see the mortality rate at 30% or lower and improved (lower) Rankin scores, they may conclude that the active is probably having an effect. Read Full Thread Follow Reply
24/9/2019 10:09	asat91: Well I was about to share similar concerns so don't regret sharing too much. The overly positive tone of the most recent RNS releases about breast cancer results are what indicate to me that they are worried about the SAH results and trying to avoid a significant share price drop. I mean why are they even releasing an RNS on the breast cancer results! The results came out a while back, and there's nothing new in these releases that requires sharing with shareholders. So why upload it at all? The timing seems very coincidental 1/2 months before SAH results. Read Full Thread Follow Reply
23/9/2019 13:46	lovewinshatelosses: So, another positive RNS and yet no great movement in the share price today so far. Do people think that this is because the statistical significance is yet to be proven on a large enough scale and/or for a long enough time period, or is it something else? Regardless, I too would like to add my best wishes to blakeysangel, whose positivity I really respect and whose updates I appreciate. Read Full Thread Follow Reply
11/9/2019 13:42	blakeysangel: Hi, Onco appointment done today and continuing on Stem SFX01 for at least another 2 months till next scan... feeling happy!! Just need the Share price rise! 😀😀😀 Read Full Thread Follow Reply
29/7/2019 12:42	pdt: hsm12 - as you say any hint of efficacy and the share price could multiply. What I think is interesting is that any hint of efficacy could be a read across to Stroke in general where the market opportunity is x20 that of SAH. Although in SAH you are trying to mitigate a delayed ischemia there seems some evidence that sfx-01 could assist recovery post the initial event. This is what they said in the Interims in December 2018; "In our collaboration with Professor Giovanni E. Mann at King's BHF Centre of Research Excellence, King's College London, we have also been investigating the effects of SFX-01 in an in-vivo model of ischaemic stroke. The studies include Laser Speckle Blood Flow Imaging, a technology that shows real-time blood flow around the brain, before, during and after an experimental stroke. Whilst still ongoing, the study has shown that preconditioning with SFX-01 (i.e. three days dosing prior to stroke) improves the blood flow to the site of the stroke and this results in improved measures of functional and motor deficit. Notably, both pre-treatment and acute treatment with SFX-01 after ischaemic stroke rescued blood flow on reperfusion, suggesting that SFX-01 is protective if given before a stroke. This is promising with regard to our SAS clinical trial, where SFX-01 is administered days in advance of the ischaemia that follows the initial haemorrhage." Certainly interesting times for Evgen. Read Full Thread Follow Reply
13/6/2018 12:14	teddy boy1: There should be a law against what has happened this morning ;the way the share price was systematically taken down to encourage more sales.This share is definitely being "worked " and the bottom line is that all the shorters and the market makers have made themselves a shed load of money over the past 3 days- and this is on a GOOD trial update ! Think of what would have happened if the news had been bad! On second thoughts the share price would not have been too much different ,left to its own devices. Anyhow this is AIM , and this is how things are ! Perhaps companys such as EVGEN and IDP with very tightly held shares should be avoided like the plague as they are prime candidates for manipulation . With such companys;until they have proved themselves 100 per cent, the seeds of doubt will be sown and before we know where we are the share price has been worked down until the share price bears no resemblance to its true value. This is a real pity as I have not read anything myself which would encourage me to dispose of my shares as, as far as I am concerned ,Evgen Pharma has a very bright future .However ,it could still be many months/years before we are allowed a TRUE share price which values the company for what it is worth and not what some individuals CAUSE it to be, in the quest to make some easy money for themselves, over and over again! Anyone else agree with my sentiments? Read Full Thread Follow Reply

Evgen Pharma share price data is direct from the London Stock Exchange

Your Recent History

LSE

EVG

Evgen Phar..

Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

ADVFN UK Investors Hub ADVFN Italy ADVFN Australia ADVFN Brazil

ADVFN Canada ADVFN Germany ADVFN Japan ADVFN Mexico

ADVFN France ADVFN US Finance Manila

P: V: D:20191023 06:03:07